Research Triangle Park, NC – According to filings with the U.S. Securities and Exchange Commission, Lindy Biosciences is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Deborah Bitterfield played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lindy Biosciences
Lindy Biosciences is a development-stage protein therapeutic formulations company. Our core technology, Microglassification, produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for incorporation into drug delivery formulations such as suspensions(for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.

To learn more about Lindy Biosciences, visit http://www.lindybio.com/

Contact:
Deborah Bitterfield, Chief Executive Officer
919-748-4480
dbitterfield@lindybio.com
https://www.linkedin.com/in/deborah-bitterfield/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved